Terms: = Pancreatic cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Prognosis
10 results:
1. Nuclear MAST4 Suppresses foxo3 through Interaction with AKT3 and Induces Chemoresistance in pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract] [Full Text] [Related]
2. ATIC inhibits autophagy in hepatocellular cancer through the AKT/foxo3 pathway and serves as a prognostic signature for modeling patient survival.
Zhang H; Xia P; Liu J; Chen Z; Ma W; Yuan Y
Int J Biol Sci; 2021; 17(15):4442-4458. PubMed ID: 34803509
[No Abstract] [Full Text] [Related]
3. SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis.
Leng S; Huang W; Chen Y; Yang Y; Feng D; Liu W; Gao T; Ren Y; Huo M; Zhang J; Yang Y; Wang Y
Cell Death Differ; 2021 Dec; 28(12):3329-3343. PubMed ID: 34163012
[TBL] [Abstract] [Full Text] [Related]
4. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
5. Expression of the PTEN/foxo3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression.
Zhang Q; Li X; Li Y; Chen S; Shen X; Dong X; Song Y; Zhang X; Huang K
Invest New Drugs; 2020 Apr; 38(2):321-328. PubMed ID: 31087222
[TBL] [Abstract] [Full Text] [Related]
6. Knockdown of foxo3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract] [Full Text] [Related]
7. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/foxo3 signaling pathway.
Yao Y; Zhou L; Liao W; Chen H; Du Z; Shao C; Wang P; Ding K
Carbohydr Polym; 2019 Jan; 204():111-123. PubMed ID: 30366522
[TBL] [Abstract] [Full Text] [Related]
8. The foxo3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.
Kumazoe M; Takai M; Hiroi S; Takeuchi C; Kadomatsu M; Nojiri T; Onda H; Bae J; Huang Y; Takamatsu K; Yamashita S; Kangawa K; Tachibana H
J Biol Chem; 2017 Jun; 292(26):10813-10823. PubMed ID: 28507102
[TBL] [Abstract] [Full Text] [Related]
9. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.
Wang J; He P; Gaida M; Yang S; Schetter AJ; Gaedcke J; Ghadimi BM; Ried T; Yfantis H; Lee D; Weiss JM; Stauffer J; Hanna N; Alexander HR; Hussain SP
Oncotarget; 2016 Aug; 7(33):52993-53004. PubMed ID: 27367029
[TBL] [Abstract] [Full Text] [Related]
10. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via foxo3a activation.
Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
[TBL] [Abstract] [Full Text] [Related]
